NRX Pharma Reports Strong 2025 Results, Eyes FDA Approval for New Therapy

NRX Pharmaceuticals (NASDAQ: NRXP) reported strong momentum in its 2025 results, highlighting reduced operating expenses, growing revenue, and a solid cash position to support operations through 2026. The company also expects potential FDA approval of its preservative-free ketamine therapy as early as Q3 2026, following positive regulatory feedback.

NRX continues advancing its pipeline with NRX-101, a breakthrough-designated treatment for severe depression and suicidality, while expanding its commercial footprint through Hope Therapeutics, a growing network of psychiatry clinics focused on innovative neuroplastic treatments.

Tags

#NRXPharmaceuticals
#NRXP
#Biotech
#MentalHealth
#KetamineTherapy
#FDAApproval
#DepressionTreatment
#ClinicalTrials
#HealthcareInnovation
#BiotechInvesting
#Neuroplasticity
#Psychiatry
#Pharmaceuticals
#AnnaBerry
#NewsOut